Skip Navigation

Cardiovascular Research 2002 53(4):806-821; doi:10.1016/S0008-6363(01)00493-X
© 2002 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bueno, O. F
Right arrow Articles by De Windt, L. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bueno, O. F
Right arrow Articles by De Windt, L. J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2002, European Society of Cardiology

Calcineurin and hypertrophic heart disease: novel insights and remaining questions

Orlando F Buenoa, Eva van Rooijb, Jeffery D Molkentina, Pieter A Doevendansb and Leon J De Windtb,*

aDivision of Molecular Cardiovascular Biology, Department of Pediatrics, Children's Hospital Medical Center, Cincinnati OH, USA
bDepartment of Cardiology, Cardiovascular Research Institute Maastricht, University Hospital Maastricht, P. Debyelaan 25, 6202 AZ Maastricht, The Netherlands

leon.dewindt{at}cardio.unimaas.nl

* Corresponding author. Tel.: +31-43-388-2949; fax: +31-43-387-5104

In the past 2 years, an emerging body of research has focused on a novel transcriptional pathway involved in the cardiac hypertrophic response. Ever since its introduction, the significance of the calcineurin–NFAT module has been subject of controversy. The aim of this review is to provide both an update on the current status of knowledge and discuss the remaining issues regarding the involvement of calcineurin in hypertrophic heart disease. To this end, the molecular biology of calcineurin and its direct downstream transcriptional effector NFAT are discussed in the context of the genetic studies that established the existence of this signaling paradigm in the heart. The pharmacological mode-of-action and specificity of the calcineurin inhibitors cyclosporine A (CsA) and FK506 is dicussed, as well as their inherent limitations to study the biology of calcineurin. A critical interpretation is given on studies aimed at analyzing the role of calcineurin in cardiac hypertrophy using systemic immunosuppression. To eliminate the controversy surrounding CsA/FK506 usage, recent studies employed genetic inhibitory strategies for calcineurin, which confirm the pivotal role for this signal transduction pathway in the ventricular hypertrophy response. Finally, unresolved issues concerning the role of calcineurin in cardiac pathobiology are discussed based upon the information available, including its controversial role in cardiomyocyte viability, the reciprocal relationship between myocyte Ca2+ homeostasis and calcineurin activity and the relative importance of calcineurin in relation to other hypertrophic signaling cascades.

KEYWORDS Apoptosis; Calcium (cellular); Cardiomyopathy; Gene expression; Heart failure; Hypertrophy; Signal transduction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Cell Physiol.Home page
A. M. Prasad and G. Inesi
Effects of thapsigargin and phenylephrine on calcineurin and protein kinase C signaling functions in cardiac myocytes
Am J Physiol Cell Physiol, May 1, 2009; 296(5): C992 - C1002.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
S. Hsu, T. Nagayama, N. Koitabashi, M. Zhang, L. Zhou, D. Bedja, K. L. Gabrielson, J. D. Molkentin, D. A. Kass, and E. Takimoto
Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway
Cardiovasc Res, February 1, 2009; 81(2): 301 - 309.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
R. Ventura-Clapier, A. Garnier, and V. Veksler
Transcriptional control of mitochondrial biogenesis: the central role of PGC-1{alpha}
Cardiovasc Res, July 15, 2008; 79(2): 208 - 217.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
A. Karatas, B. Hegner, L. J. de Windt, F. C. Luft, C. Schubert, V. Gross, Y. J. Akashi, D. Gurgen, U. Kintscher, A. C. da Costa Goncalves, et al.
Deoxycorticosterone Acetate-Salt Mice Exhibit Blood Pressure-Independent Sexual Dimorphism
Hypertension, April 1, 2008; 51(4): 1177 - 1183.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
A. V. Zima, D. J. Bare, G. A. Mignery, and L. A. Blatter
IP3-dependent nuclear Ca2+ signalling in the mammalian heart
J. Physiol., October 15, 2007; 584(2): 601 - 611.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.